At this year’s ECTRIMS conference, significant updates to the diagnostic criteria for relapsing MS were discussed, enabling earlier diagnosis and treatment, which is crucial for long-term patient outcomes, according to Dr Devon S. Conway. Notably, some dissemination in time requirements have been eliminated, and the criteria for diagnosing radiologically isolated syndrome have been broadened.
The conference also highlighted several promising new therapies in development with novel mechanisms of action, such as BTK inhibitors and RIPK1 inhibitors, which may offer more options for patients who do not respond well to current drugs. Overall, the event showcased meaningful progress in both the diagnosis and treatment landscape for relapsing MS.
